Clinical Trial Update: Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating dasatinib in patients with recurrent glioblastoma multiforme or gliosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2015-01-06